Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

Inclusion Criteria:

1. Focal, segmental, or generalized (i.e., nonsegmental) stable vitiligo, defined as nonew depigmented areas nor any depigmented areas that have expanded in size withinthe preceding 12 months.

2. The patient is a candidate for surgical intervention of a depigmented area, definedas a patient who has not satisfactorily responded to either:

3. topical therapy or

4. a minimum of 3 months of phototherapy.

5. The patient has a depigmented area available for treatment that is:

6. ≥90% depigmented,

7. without any other dermatologic conditions (other than vitiligo), and

8. excludes the lips, eyelids, plantar surface of feet, palmar surface of hands.

9. The patient is 18 years of age or older.

10. The patient agrees to remain on any current use of immunosuppressive therapy for theduration of his/her participation in the study (52 weeks).

11. The patient is willing and able to comply with post-treatment at-home phototherapyand all follow-up study visits.

12. The patient agrees to abstain from any other treatment of the study area for theduration of his/her participation in the study (52 weeks).

13. The patient agrees to abstain from enrollment in any other interventional clinicaltrial for the duration of his/her participation in the study (52 weeks).

14. In the opinion of the investigator, the patient must be able to:

15. Understand the full nature and purpose of the study, including possible risksand benefits,

16. Understand instructions and be able to comprehend and complete studyquestionnaires, and

17. Provide voluntary written informed consent. -

Exclusion Criteria:

1. The patient is unable to undergo treatment area preparation.

2. Patients who received RECELL treatment for vitiligo in Protocol No. CTP008 orCTP009.

3. Patients with:

4. depigmented lips and fingertips (lip-tip vitiligo), or

5. depigmented areas over >30% of their body surface area.

6. Patients with recent history (within previous 12 months) of:

7. Koebnerization,

8. confetti-like, or

9. trichrome lesions.

10. Patients with a history of keloid formation.

11. The patient has other concurrent conditions that in the opinion of the investigatormay compromise patient safety or study objectives.

12. Current use of medications (e.g., anticoagulants such as heparin or warfarin) thatin the investigator's opinion may compromise patient safety or trial objectives.

13. The patient has a known hypersensitivity to trypsin, compound sodium lactate forirrigation solution (Hartmann's solution), povidone-iodine, chlorhexidine, and/orlidocaine-containing anesthetics -